RIPK3 and neoplasm: Regardless of the RIPK3 status in tumor cells, using optogenetically activatable MLKL can still trigger the release of both cDAMPs and iDAMPs, demonstrating its ability to elicit an immune response independent of upstream RIPK3 signaling.